NOTRELOAD AI
  • NOTRELOAD AI
  • Stocks BUZZ.
  • #TrumpTrade
  • 24-HOUR Pass →
  • Invest ↗
Sign in Subscribe

FDA Approves First Treatment for Rare Menkes Disease

ZYCUBO becomes the first FDA-approved treatment for Menkes disease, a rare genetic disorder affecting copper transport in children, offering new hope for patients.

FDA Approves First Treatment for Rare Menkes Disease
Credit: Fortress Biotech
Already have an account? Sign in.
01/13/2026 · 8:11 AM
FBIO
/ Don't stop with just one post.

Related↓

10/01/2025 · 9:12 AM

Fortress Biotech Stock Plummets After FDA Rejection

FDA rejected Fortress Biotech's Menkes drug, CUTX-101, due to factory issues, but the drug's safety and efficacy data were fine.

/ Subscriber only
/ Read more

Feed↓

Evercore ISI Starts Coverage on Reddit with Bullish Outlook
Featured/ 01/13/2026 · 10:14 AM

Evercore ISI Starts Coverage on Reddit with Bullish Outlook

Evercore ISI initiates coverage on Reddit with an Outperform rating and $320 price target, citing strong growth, improving monetization, and rising ad potential.

/ Subscriber only
Goldman Sachs Starts Coverage on Super Micro With a Sell Rating
Featured/ 01/13/2026 · 10:06 AM

Goldman Sachs Starts Coverage on Super Micro With a Sell Rating

Goldman Sachs initiates coverage on Super Micro with a Sell rating, citing margin pressure, rising competition, and limited profit visibility despite AI leadership.

/ Subscriber only
Travere Therapeutics Stock Plunges on FDA Approval Uncertainty
01/13/2026 · 9:30 AM

Travere Therapeutics Stock Plunges on FDA Approval Uncertainty

Travere Therapeutics shares drop 33% in premarket as FDA requests more data for FILSPARI FSGS approval, delaying potential first-ever treatment for rare kidney disease.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2025
Email address Subscribe